QUOTE AND NEWS
TheStreet.com  Feb 5  Comment 
Our biotech columnist answers readers' burning questions about Soligenix, Cell Therapeutics, and other biotech stocks.
StreetInsider.com  Jan 25  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Osiris+Therapeutics+%28OSIR%29+to+Receive+%24750K+from+Prochymal+Phase+II+Completion/5270575.html for the full story.
Business Wire  Jan 25  Comment 
Osiris Therapeutics, Inc. (NASDAQ:OSIR) today announced that it has achieved a $750,000 milestone payment from the Juvenile Diabetes Research Foundation (JDRF) for completing enrollment in a Phase II clinical trial evaluating Prochymal, an adult
Business Wire  Nov 25  Comment 
Osiris Therapeutics, Inc. (NASDAQ:OSIR), the leading stem cell therapeutic company focused on developing products to treat medical conditions in the inflammatory, orthopedic and cardiovascular areas, announced today that C. Randal Mills, Ph.D.,
Stock Blog Hub  Nov 15  Comment 
Osiris Therapeutics (OSIR) reported a net loss of 21 cents per share in the third quarter of 2009, well above the Zacks Consensus Estimate of a net income of 6 cents. However, net loss in the year ago period was higher at 63 cents, mainly due to...
Penny Sleuth  Sep 18  Comment 
On Wednesday, Septemer 23, one CEO’s presentation to the biotechnology community could change the future as we know it – and make you incredibly wealthy in the process… Now, with one company’s failure all but assured, our path to stem...
Stock Blog Hub  Sep 9  Comment 
We are disappointed with the failure of Osiris Therapeutics’ (OSIR) Prochymal, a drug derived from human stem cell for the treatment of graft-versus-host disease (GvHD), the most common complication of bone marrow transplants. Currently, there...
New York Times  Sep 9  Comment 
The failure of Prochymal, from Osiris Therapeutics, is a setback for the use of adult stem cells to fight organ rejection.



Thank you for your suggestion


 




References

Wikinvest © 2006, 2007, 2008, 2009, 2010. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki